Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Exelixis Inc (EXEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,604,718
  • Shares Outstanding, K 298,040
  • Annual Sales, $ 452,480 K
  • Annual Income, $ 154,230 K
  • 36-Month Beta 1.94
  • Price/Sales 10.72
  • Price/Cash Flow 29.75
  • Price/Book 6.26

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 0.19
  • Number of Estimates 6
  • High Estimate 0.31
  • Low Estimate 0.10
  • Prior Year 0.26
  • Growth Rate Est. (year over year) -26.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.72 +0.68%
on 10/23/18
18.32 -19.10%
on 10/03/18
-1.94 (-11.58%)
since 09/21/18
3-Month
14.72 +0.68%
on 10/23/18
23.19 -36.09%
on 08/02/18
-6.51 (-30.52%)
since 07/23/18
52-Week
14.72 +0.68%
on 10/23/18
32.20 -53.98%
on 01/04/18
-12.16 (-45.07%)
since 10/23/17

Most Recent Stories

More News
Exelixis to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018

Exelixis, Inc. (NASDAQ: EXEL) announced today that its third quarter 2018 financial results will be released on Thursday, November 1, 2018 after the markets close. At 5:00 p.m. EDT...

EXEL : 14.82 (-4.08%)
Exelixis Inc Down 36.7% Since SmarTrend Downtrend Call (EXEL)

SmarTrend identified a Downtrend for Exelixis Inc (NASDAQ:EXEL) on February 28th, 2018 at $26.69. In approximately 8 months, Exelixis Inc has returned 36.74% as of today's recent price of $16.88.

EXEL : 14.82 (-4.08%)
Report: Exploring Fundamental Drivers Behind Bellicum Pharmaceuticals, Social Reality, Exelixis, Edgewell Personal Care, Cronos Group, and Acacia Communications -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Bellicum Pharmaceuticals,...

SRAX : 2.52 (-6.32%)
SCRI : 1.3000 (unch)
CRON : 8.34 (-2.11%)
ACIA : 37.74 (-1.46%)
EPC : 44.55 (-3.55%)
EXEL : 14.82 (-4.08%)
BLCM : 4.97 (+0.40%)
Exelixis Inc Falls 3.33% on Heavy Volume: Watch For Potential Rebound

Exelixis Inc (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $15.49 to a high of $16.20. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $15.84...

EXEL : 14.82 (-4.08%)
Cabozantinib to Be Featured in 13 Presentations at ESMO 2018 Congress

Exelixis, Inc. (NASDAQ:EXEL) today announced that data from clinical trials of cabozantinib will be the subject of 13 presentations at the European Society for Medical Oncology (ESMO)...

EXEL : 14.82 (-4.08%)
Exelixis Inc Shares Down 35.5% Since SmarTrend's Sell Call (EXEL)

SmarTrend identified a Downtrend for Exelixis Inc (NASDAQ:EXEL) on February 28th, 2018 at $26.69. In approximately 7 months, Exelixis Inc has returned 35.47% as of today's recent price of $17.22.

EXEL : 14.82 (-4.08%)
Why the Earnings Surprise Streak Could Continue for Exelixis (EXEL)

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

EXEL : 14.82 (-4.08%)
Exelixis Initiates Phase 3 Pivotal Trial (COSMIC-311) of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy

Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of a phase 3 pivotal trial (COSMIC-311) of single-agent cabozantinib in patients with radioiodine-refractory differentiated...

EXEL : 14.82 (-4.08%)
Liver Cancers Rising - Stocks to Watch

HENDERSON, NV / ACCESSWIRE / October 5, 2018 / Liver cancer incidence has more than tripled since 1980. Liver cancer death rates have increased by almost 3% per year since 2000. More than 700,000 people...

VKTX : 13.71 (+1.26%)
ENTA : 77.14 (-0.86%)
EXEL : 14.82 (-4.08%)
DCTH : 0.5400 (-9.24%)
Exelixis to Present at the Cantor Fitzgerald Global Healthcare Conference on October 2, 2018

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide an overview of the company at the Cantor...

EXEL : 14.82 (-4.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade EXEL with:

Business Summary

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ' (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another...

See More

Key Turning Points

2nd Resistance Point 15.54
1st Resistance Point 15.18
Last Price 14.82
1st Support Level 14.59
2nd Support Level 14.36

See More

52-Week High 32.20
Fibonacci 61.8% 25.52
Fibonacci 50% 23.46
Fibonacci 38.2% 21.40
Last Price 14.82
52-Week Low 14.72

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar